Michael Perkins, MD
Pulmonary Disease · Savannah, GANPI 1659472017
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $62,950 of the $66,531 with a category attached, or 94.6%. GSK accounts for 96.8% of it on its own, with 26 other manufacturers making up the rest. Reporting peaked in 2022 at $27,901 and has fallen 98.7% since, to $362 in 2025. Among pulmonary disease clinicians in GA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 203 payments — averaging $327.74 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- GSK$64K
- Abiomed$419
- AstraZeneca$312
- Boehringer Ingelheim$183
- Regeneron Healthcare Solutions, Inc.$182
- Electromed, Inc.$181
- plus $835 from 21 others
What the payments were for
- Speaking & faculty fees$62,95095%
- Food & beverage$3,5545%
- Education$280%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| GSK | 80 | $64,419 |
| Abiomed | 5 | $419 |
| AstraZeneca | 22 | $312 |
| Boehringer Ingelheim | 11 | $183 |
| Regeneron Healthcare Solutions, Inc. | 7 | $182 |
| Electromed, Inc. | 27 | $181 |
| Actelion Pharmaceuticals US, Inc. | 8 | $135 |
| Pulmonx Corporation | 2 | $95 |
| Sunovion Pharmaceuticals Inc. | 7 | $77 |
| United Therapeutics Corporation | 5 | $73 |
| Insmed, Inc. | 4 | $50 |
| Mallinckrodt Hospital Products Inc. | 2 | $45 |
| Mylan Specialty L.p. | 3 | $43 |
| Genentech USA, Inc. | 2 | $41 |
| Portola Pharmaceuticals, LLC | 2 | $39 |
| Eisai Inc. | 2 | $32 |
| Sanofi | 2 | $32 |
| Jazz Pharmaceuticals Inc. | 2 | $29 |
| Merck | 2 | $24 |
| Shire North American Group Inc | 1 | $18 |
| Grifols USA, LLC | 1 | $18 |
| AbbVie | 1 | $16 |
| Harmony Biosciences LLC | 1 | $15 |
| Fisher & Paykel Healthcare Inc | 1 | $14 |
| Johnson & Johnson | 1 | $14 |
| Novartis | 1 | $13 |
| Mallinckrodt Enterprises LLC | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- TRELEGY ELLIPTA$23,318
- ANORO ELLIPTA$3,600
- Impella$110
How this compares
$66,531 in reported general payments places this provider in the 95th percentile of 365 pulmonary disease providers in Georgia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other pulmonary disease in Savannah
- Lawrence McDermottSavannah$963K
- Michael MullinsSavannah$132K
- Ryan MoodySavannah$50K
- Gifford LorenzSavannah$20K
- Vivek SambharaGainesville$417K
- Chad MillerAustell$382K
- Nehal BhattAthens$371K
- Maria MascoloRincon$358K
- Colin SwensonAtlanta$255K
- David MillerDecatur$206K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.